BiotechTube

NNZ-2591

Phase 2Completed
0 watching 0 views this week⚡ Active
47
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Angelman Syndrome

Conditions

Angelman Syndrome

Trial Timeline

Jul 12, 2022 → Jul 16, 2024

NCT ID
NCT05011851

About NNZ-2591

NNZ-2591 is a phase 2 stage product being developed by Neuren Pharmaceuticals for Angelman Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT05011851. Target conditions include Angelman Syndrome.

Hype Score Breakdown

Clinical
17
Activity
12
Company
5
Novelty
5
Community
5

Clinical Trials (4)

NCT IDPhaseStatus
NCT05879614Phase 2Withdrawn
NCT05025332Phase 2Completed
NCT05025241Phase 2Completed
NCT05011851Phase 2Completed

Competing Products

9 competing products in Angelman Syndrome

See all competitors
ProductCompanyStageHype Score
RO7248824RochePhase 1
33
RO7248824RochePhase 1
33
AlogabatRochePhase 2
52
ION582Ionis PharmaceuticalsPhase 1/2
38
ION582 + PlaceboIonis PharmaceuticalsPhase 3
74
GTX-102Ultragenyx PharmaceuticalPhase 3
72
GTX-102Ultragenyx PharmaceuticalPhase 3
72
GTX-102Ultragenyx PharmaceuticalPhase 2
47
GTX-102Ultragenyx PharmaceuticalPhase 1/2
36

Other Products from Neuren Pharmaceuticals

NNZ-2591 + PlaceboPhase 3
72
NNZ-2566 + PlaceboPhase 2
47
NNZ-2566 + PlaceboPhase 2
47
NNZ-2566 + PlaceboPhase 2
47
NNZ-2591Phase 2
47